Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108

PURPOSE: Malignant ascites is debilitating for patients with advanced cancer. As shown previously, tumour cell production of vascular endothelial growth factor might be a major cause of the formation of malignant ascites. Intraperitoneal bevacizumab could therefore be an option for symptom control in refractory ascites. PATIENTS AND METHODS: Patients with advanced gastrointestinal cancer and malignant ascites who had undergone paracentesis at least twice within the past 4 weeks were randomly assigned in a 2:1 ratio to intraperitoneal bevacizumab (400 mg absolute) or placebo after paracentesis. During the 8-week treatment period, a minimum interval of 14 d was kept between the applications of the study drug. Primary end-point was paracentesis-free survival (ParFS). RESULTS: Fifty-three patients (median age 63 years) were randomised. Forty-nine patients received at least one study drug application and qualified for the main analysis. The proportion of patients with at least one common toxicity criteria grade III-V event was similar with 20/33 (61%) on bevacizumab and 11/16 (69%) on placebo. Median ParFS was 14 d (95% confidence interval [CI]: 11-17) in the bevacizumab arm and 10.5 d (95% CI: 7-21) on placebo (hazard ratio 0.74, 95% CI: 0.40-1.37; P = 0.16). The longest paracentesis-free period was 19 d on bevacizumab (range 6-66 d) and 17.5 d in the placebo arm (range 4-42) (P = 0.85). Median overall survival was 64 d (95% CI: 45-103) on bevacizumab compared to 31.5 d (95% CI: 20-117) on placebo (P = 0.31). CONCLUSION: Intraperitoneal bevacizumab was well tolerated. Overall, treatment did not result in a significantly better symptom control of malignant ascites. However, patients defined by specific immune characteristics may benefit.

Diferenciación sexual del lenguado de California Paralichthys californicus y control de la proporción sexual mediante la utilización de la hormona 17β-estradiol

El lenguado de California Paralichthys californicus es una especie con alto valor comercial debido a su gran tamaño y calidad de su carne. Esta especie presenta dimorfismo sexual en el crecimiento donde las hembras crecen más rápido que los machos, por lo tanto el cultivo monosexual de hembras resulta favorable para la producción. En el presente estudio se registró el proceso de diferenciación sexual mediante cortes histológicos de las larvas y gónadas del lenguado de California asimismo se probó el efecto de diferentes concentraciones de 17β-estradiol (E2) (2.5, 5 y 10 mg/kg) a través de la dieta para incrementar la proporción de hembras en el cultivo. A los 25 días después de la eclosión (DDE) se observó el primordio gonadal en ejemplares con una longitud total promedio de 6.96 ± 0.92 mm, hasta el día 75 DDE (37.58 ± 6.58 mm) se observó una gónada indiferenciada evidenciada por la presencia de células germinales primordiales. La primera evidencia de diferenciación se registró a los 115 DDE (55.93 ± 14.67 mm) donde se observó la cavidad ovárica y posteriormente a los 180 DDE (115.70 ± 17.02 mm) se evidencian ovarios con ovocitos en crecimiento y testículos con espermátidas. Por lo tanto, el periodo lábil para la diferenciación sexual se encuentra entre los días 75 y 115 después de la eclosión. Por otro lado, el suministro de E2 a través de la dieta a concentraciones de 2.5, 5 y 10 mg/kg incrementó el porcentaje de hembras de 26.67% (control, no adición de E2) a un 100% en todos los tratamientos. Se encontraron diferencias en la proporción de los tipos celulares (ovogonias, ovocitos primarios en fase I y II) entre el control y los tratamientos mientras que no se registraron alteraciones histológicas como atrofia gonadal en ninguno de los casos.

The development of UTCS/NETSIM/ICG: an integrated urban traffic control system - network simulation - interactive computer graphics program. Final report.

Transportation Department, Office of University Research, Washington, D.C.

Traffic control systems handbook - 1985. Revised edition. Final report.

Federal Highway Administration, Office of Implementation, Washington, D.C.

Planning and scheduling work zone traffic control - technical report. Final report.

Federal Highway Administration, Office of Research, Washington, D.C.

Speed control on high speed roads. Final report.

Federal Highway Administration, Traffic Systems Division, Washington, D.C.

Closed loop control of automotive engines. Final report.

National Highway Traffic Safety Administration, Office of Research and Development, Washington, D.C.

Stop, yield, and no control at intersections. Final report.

Federal Highway Administration, Office of Research and Development, Washington, D.C.

Planning and scheduling work zone traffic control. Executive summary.

Federal Highway Administration, Office of Research, Washington, D.C.

Planning and scheduling work zone traffic control. Final technical report.

Federal Highway Administration, Office of Research, Washington, D.C.

Identification of approaches for the control of health, environmental, and safety hazards associated with air bag use and disposal. Final report.

National Highway Traffic Safety Administration, Washington, D.C.

Planning and scheduling work zone traffic control. User's guide.

Federal Highway Administration, Office of Research, Washington, D.C.

Effectiveness of speed control signs in rural school zones and small communities. Final report.

Federal Highway Administration, Office of Research, Washington, D.C.

An electronic surveillance and control system for traffic management of the Borman expressway. Final report.

Indiana Department of Transportation, Indianapolis

Evaluation of traffic control plans at reconstruction sites. Final report.

Texas State Department of Highways and Public Transportation, Transportation Planning Division, Austin